SSShoyo Shibata

Shoyo Shibata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shoyo Shibata has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Takeshi Suzuki

    Education Research Center for Pharmaceutical Sciences, Faculty of Pharmacy, Keio University

    8 shared publications
  • Koken Ozaki

    Graduate School of Business Sciences, Humanities, and Social Sciences, University of Tsukuba

    7 shared publications
  • Takeshi Suzuki

    Division of Basic Biological Sciences, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan

    6 shared publications
  • Maiko Matsushita

    Division of Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan

    5 shared publications
  • Daigo Fukumoto

    Education Research Center for Pharmaceutical Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan

    4 shared publications
  • Ryotaro Uemura

    Division of Basic Education, Faculty of Pharmacy, Keio University, Tokyo, Japan

    4 shared publications

Latest Publications

  • Open Access

    Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research

    by Shoyo Shibata, Koken Ozaki, Takeshi Suzuki

    The Japanese pharmaceutical market is one of the largest in the world. The Japanese government has increasingly been trying to control rising health care costs, and as a result, pharmaceutical companies are expecting that fewer opportunities will be available to command a higher price based on higher levels of innovation; this will likely lead to decreased interest in research and development (R&D) activities. With this background, the purpose of this article is to review current perspectives for R&D by the Japanese pharmaceutical industry, and to discuss the limitations and challenges for further research from the regulatory science and management perspectives. Given the substantial amount of evidence of regulatory science and management perspectives from the pharmaceutical industry outside of Japan and the limited amount of evidence from inside of Japan, it is important to review perspectives focusing on the Japanese pharmaceutical industry in comparison with those from other countries to understand the complexities of the Japanese pharmaceutical market, as well as the limitations and challenges associated with increasing productivity. https://doi.org/10.21423/jrs-v08shoyo


  • Analysis of new molecular entity trends from 2006 to 2015 in Japan

    by Shoyo Shibata, Daigo Fukumoto, Koken Ozaki, Takeshi Suzuki

    Japan is one of the largest pharmaceutical markets in the world, and as such, pharmaceutical companies are intensively conducting research and development of new drugs in Japan. However, information on Japanese pharmaceutical market profiles is limited. In this context, we elucidated the market characteristics and trends of new molecular entities approved between 2006 and 2015 in Japan. Among antineoplastic and immunomodulating agents, the highest number was first approved in the United States, and for nervous system drugs, the highest number was first approved in Europe. The alimentary tract and metabolism and the musculoskeletal system were the therapeutic areas for which the most drugs were approved for the first time in Japan. Most of the musculoskeletal system drugs were developed by Japanese companies, and most of the antineoplastic and immunomodulating agents were developed outside of Japan. Using various performance indexes, such as market forecasts and significance of clinical benefits, we determined that the number of new molecular entities and market size increased and the number of drugs with significant clinical benefits decreased. These results suggest that new molecular entity innovation by Japanese companies has been decreasing and the government’s comparative method for pricing does not work well in Japan.

  • A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl–Hirschman Index

    by Shoyo Shibata, Daigo Fukumoto, Takeshi Suzuki, Koken Ozaki

    As of 2015, the Japanese pharmaceutical market was the world’s third largest pharmaceutical market. Although previous studies have examined market differences in terms of market size and pricing policy, little is known about comparative market configurations. The present study provides a comparative analysis of pharmaceutical market configurations in Japan and five other markets.


  • Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy

    by Shoyo Shibata, Daigo Fukumoto, Takeshi Suzuki, Koken Ozaki

    Background: Predictions of drug sales play an important role in setting drug prices in Japan, where drug prices are highly regulated. One of 2 primary Japanese drug-pricing methodologies—the cost calculation method— refers extensively to the prediction of drug sales in establishing drug prices. Deviations from predicted sales can induce disproportionate drug prices and unexpected pharmaceutical expenditures. This study aimed to estimate the upward deviation of actual sales from predicted sales and to explore the predictors of such upward deviation. Methods: Estimates of upward deviation in 2015 were produced for new molecular entities (NMEs) approved in 2006-2015. To identify the predictors associated with upward deviation through binary logistic regression analyses, sales within 3 years of launch and in the predicted year in which peak sales would be reached were used. Results: Estimated upward deviation was more than 1220 billion yen in 2015 for the targeted drugs. Drugs priced by the cost calculation method or by obtaining additional indications were significantly more likely to show an upward deviation from predicted peak sales. Conclusions: There is substantial upward deviation between actual and predicted drug sales in Japan. So long as drug sales predictions are used in drug price calculations, a flexible repricing system is needed to buffer unexpected pharmaceutical expenditures.


  • Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy

    by Shoyo Shibata, Daigo Fukumoto, Takeshi Suzuki, Koken Ozaki

    Background: Predictions of drug sales play an important role in setting drug prices in Japan, where drug prices are highly regulated. One of 2 primary Japanese drug-pricing methodologies—the cost calculation method— refers extensively to the prediction of drug sales in establishing drug prices. Deviations from predicted sales can induce disproportionate drug prices and unexpected pharmaceutical expenditures. This study aimed to estimate the upward deviation of actual sales from predicted sales and to explore the predictors of such upward deviation.Methods: Estimates of upward deviation in 2015 were produced for new molecular entities (NMEs) approved in 2006-2015. To identify the predictors associated with upward deviation through binary logistic regression analyses, sales within 3 years of launch and in the predicted year in which peak sales would be reached were used.Results: Estimated upward deviation was more than 1220 billion yen in 2015 for the targeted drugs. Drugs priced by the cost calculation method or by obtaining additional indications were significantly more likely to show an upward deviation from predicted peak sales.Conclusion: There is substantial upward deviation between actual and predicted drug sales in Japan. So long as drug sales predictions are used in drug price calculations, a flexible repricing system is needed to buffer unexpected pharmaceutical expenditures.


  • Japan oncology market overview: Current and future perspectives

    by Shoyo Shibata, Maiko Matsushita, Takeshi Suzuki, Koken Ozaki

    The anti-cancer drug market is considered a growth market in Japan and across the world. Pharmaceutical companies have made every effort to deliver innovative drugs in this field, boosting market growth. In their research and development of anti-cancer drugs, these pharmaceuticals need to identify the optimal drug modalities in order to maximize profit, as the drugs are divided into two groups: cytotoxic-based drugs and target-based drugs. Although there have been numerous studies focused on the critical role of molecular target cancer therapy in anti-cancer drug development in Japan and elsewhere, few studies have quantitatively assessed the Japanese market using actual prescription data. This article provides an overview of the anti-cancer drug market in Japan as a foundation for formulating a global business strategy. It identifies key characteristics of the Japanese anti-cancer drug market and offers a prognosis of the market based on study findings.


  • Open Access

    Can Rare Cancer Drugs Expect Sales in Japan?: A Prescription Pattern Analysis of Drugs for Chronic Myelogenous Leukemia and Neuroendocrine Tumor

    by Shoyo Shibata, Emi Noguchi, Maiko Matsushita, Takeshi Suzuki, Koken Ozaki

    Despite high unmet medical needs, investment in rare cancer drug development has stagnated, likely because the potential market for such drugs is small. In this context, we hypothesized that rare cancer drugs could achieve a higher sales margin. A dataset was created from publicly available information obtained from the IQVIA Solutions Japan K.K. Pharmaceutical Market database on the website of the Pharmaceuticals and Medical Devices Agency/Ministry of Health, Labour and Welfare of Japan. The total amount of sales and prescription volumes between 2010 and 2016 for drugs whose indications include chronic myelogenous leukemia (CML) and neuroendocrine tumor (NET) were investigated. Regarding drugs for CML, the sales and prescription volumes of imatinib have been decreasing every year, whereas those of dasatinib and nilotinib have been increasing. Regarding drugs for NET, the sales and prescription volumes of sunitinib, everolimus, and streptozocin have been increasing every year. The present study revealed two sales models for the development of rare cancer drugs. First, sales amounts can be assured if clinical positioning with other existing drugs is sufficiently clear. Second, obtaining a label for rare cancers can stimulate drug development for more common cancers. These findings suggest that rare cancer drugs can offer high market value and profit potential; thus, to meet high unmet medical needs, clinical development programs for the development of rare cancer drugs should be promoted. https://doi.org/10.21423/jrs-v07shibata


  • Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy

    by Shoyo Shibata, Maiko Matsushita, Yoshimasa Saito, Takeshi Suzuki

    Despite their benefits, the rapid development of new cancer treatments has been a significant driver of increasing health care expenditures in the face of limited health care budgets. In this study, we analyzed the prescribing trends for anticancer drugs from 2010 through 2016 in Japan and sought to identify unique trends that could provide a basis for future medical economic research aiming to develop more efficacious and cost-effective cancer therapies. We used publicly available marketing data for anticancer drugs in Japan for 2010-2016. The drugs selected for this research were categorized according to the Anatomical Therapeutic Chemical Classification System. We investigated the overall anticancer drug market size, the number of anticancer drugs, the top 30 selling anticancer categories, sales and prescription volumes, and changes in sales and prescription volumes between 2010 and 2016 in the country. The anticancer agent market expanded each year from 2010 to 2016, with sales exceeding 1 trillion yen in 2015. The proportion of molecular targeted drugs (antineoplastic mAbs and protein kinase inhibitors) among the top 30 selling anticancer categories has continued to increase, and both the sales and prescription volumes of these drugs exceeded those of drugs in other categories, suggesting that these treatments play a dominant role in cancer pharmacotherapy. The availability and increasing use of innovative but more expensive targeted therapies were major drivers of increases in pharmaceutical expenditures for cancer treatment in Japan. Therefore, the effective use of genetic testing can mitigate these rising costs.


  • Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan

    by Shoyo Shibata, Maiko Matsushita, Yoshimasa Saito, Takeshi Suzuki

    The increased use of generic drugs is a good indicator of the need to reduce the increasing costs of prescription drugs. Since there are more expensive dru


  • An Empirical Study of the Prescription Pattern of Drugs for Hematological Malignancies in Japan from 2010–2014

    by Shoyo Shibata, Yusuke Wayama, Ai Tsuyuki, Maiko Matsushita, Koji Chiba, Eri Matsuki, Shinichiro Okamoto, Takeshi Suzuki

    The number of elderly patients with hematologic malignancies has been steadily increasing with the aging of society. However, little research has been conducted to evaluate the prescription status of drugs for such diseases in Japan. Therefore, the aims of this study were to identify the patient population currently being prescribed drugs for hematologic malignancies in Japan and the direction of drug development. To examine the prescription pattern of drugs for the treatment of hematological malignancies in Japan from 2010-2014, we used the IMS Japan Pharmaceutical Market database and the Japanese Society of Hematology Clinical Practice Guidelines, and for drug development status, we used ClinicalTrials.gov and the University Hospital Medical Information Network Clinical Trials Registry. We found a significant upward trend in prescriptions for molecular-targeted agents, which are typically prescribed over the long term, and a significant downward trend in chemotherapeutic agents, which are usually prescribed for the short term. We also found that recent drug development in hematological malignancies has focused on molecular-targeted agents. These results suggest that drug development should be directed toward anti-tumor agents in hematological malignancies that can help maintain and improve patients' QOL.